The relation of oral contraceptive use to the risk of breast cancer in white women aged 25-59 years was assessed with data collected during 1977-1992 in a case-control surveillance system in hospitals in Boston, New York, and Philadelphia. A total of 3,540 cases with breast cancer were compared with 4,488 controls with nonmalignant nongynecologic conditions unrelated to oral contraceptive use. Relative risk estimates were obtained by unconditional logistic regression with control for major risk factors. For at least 1 year of use relative to less than 1 year, the multivariate relative risk estimate was 1.7 (95% confidence interval (Cl) 1.3-2.3) in women aged 25-34 years, 0.9 (95% Cl 0.7-1.0) in women aged 35-44 years, and 1.2 (95% Cl 1.0-1.4) in women aged 45-59 years (p < 0.01 for the difference across age). Among women aged 25-34 years, the relative risk estimates were greatest for use of long duration, but the trend was not statistically significant (p = 0.17); in addition, the duration of use was con-elated with the recency of use, and It was not possible to distinguish their effects. Among women aged 35-44 years, the relative risk estimate decreased with increasing duration of use (p = 0.01). Among women aged 45-59 years, some relative risk estimates were increased, but there was no consistent pattern. The results add to the evidence of an association between oral contraceptive use and an increased risk of breast cancer at young ages. Am J Epidemiol 1996;143:25-37. breast neoplasms; contraceptives, oral; women Oral contraceptives were first used commonly by women who had already borne children. In recent years, use for long periods early in reproductive life has become common. Early epidemiologic studies of oral contraceptive use in relation to breast cancer at older ages yielded null results, but recent studies of younger women have tended to be positive (1-5). There have been inconsistent findings in subgroups: Increased risk has been related to use of long duration, at young ages, before a first birth, in the relatively recent past, and among women with a family history of breast cancer.
Oral contraceptives were first used commonly by women who had already borne children. In recent years, use for long periods early in reproductive life has become common. Early epidemiologic studies of oral contraceptive use in relation to breast cancer at older ages yielded null results, but recent studies of younger women have tended to be positive (1) (2) (3) (4) (5) . There have been inconsistent findings in subgroups: Increased risk has been related to use of long duration, at young ages, before a first birth, in the relatively recent past, and among women with a family history of breast cancer.
We have published several reports on oral contraceptive use and breast cancer based on data from a multipurpose hospital-based surveillance system be-gun 20 years ago. The results for older women have been null or weakly positive (6, 7) . For younger women, in a report on data collected until 1981, there was a statistically significant increased risk for longterm users (6) . In a subsequent report based on data collected until 1983, long-term use before the first birth was weakly associated with an increased risk (8) . In data collected from 1983 to 1986, there was a stronger association with the total duration of use (9) . Most of the women studied were white.
We report here on the relation of oral contraceptive use to breast cancer risk in white women, based on a total of 3,540 cases and 4,488 controls interviewed from the beginning of the surveillance study to 1992, of whom 876 cases and 780 controls were interviewed •after 1986. The large database allowed for assessment of several hypotheses of current interest, particularly in younger women, and for assessment of variation in associations over time.
MATERIALS AND METHODS

Data collection
The data were collected in our Case-Control Surveillance Study, which has been in progress since late 1976. Nurse-interviewers stationed in hospitals in several cities administered standard questionnaires to pa-tients under 70 years of age. Patients were selected according to a priority list of diagnoses which changed from time to time; varying proportions of patients with any particular diagnosis were interviewed. Information was collected on demographic factors, medical and reproductive history, and cigarette and alcohol use. Lifetime medication history was obtained by asking about 40 different indications for medication use; for oral contraceptive use, these indications included contraception, regulation of periods, menstrual problems, and endometriosis. For each episode of use, the product used, the date use started, and the duration of use were recorded. Discharge summaries and pathology reports were used to classify the patients' diagnoses. Of patients approached for an interview, 95 percent participated.
The present analyses are based on data collected during the period 1977-1992 from white women aged 25-59 years in hospitals in Boston, New York, and Philadelphia, the centers at which over 90 percent of the patients with breast cancer in the surveillance study were interviewed. Women aged 60 years or more were not included because of their low prevalence of oral contraceptive use.
Cases
The cases were 3,540 women aged 25-59 years with first occurrences of primary breast cancer (diagnosed within the previous year) and no concurrent cancer or history of cancer.
Controls
The controls were 4,488 women aged 25-59 years with no history of cancer who had been admitted for nongynecologic nonmalignant conditions judged to be unrelated to oral contraceptive use or reproductive factors. They were frequency-matched to the cases on half-decade of age and, if possible, also on geographic area, up to a ratio of 4:1. For women under age 35, the ratio was 2.6: 1; beyond age 34, the ratio was close to. 1.0. The admission diagnoses of the controls included orthopedic disorders (25 percent), traumatic injury (22 percent), acute infections (17 percent), and a variety of other conditions (36 percent). Prevalences of oral contraceptive use, adjusted to the distribution by age, geographic area, and interview year of the total control series, were similar across the four diagnostic categories: The prevalence of never use was 55.4-58.4 percent; that of 1-11 months of use was 10.3-13.1 percent; that of 1-4 years of use was 15.2-17.6 percent; and the prevalence of 5 or more years of use was 12.2-14.2 percent.
Data analysis
Unconditional logistic regression was used to estimate relative risks (odds ratios) for various categories of oral contraceptive use with control for potentially confounding factors (10) .
As is shown in table 1, cases were more likely than controls to have higher levels of education, to be Jewish, to have a mother or sister with breast cancer, to have physician-diagnosed benign breast disease, to consume alcohol (at least once per month for at least 1 year), to practice breast self-examination, and to have an early menarche, a late age at first birth, lower parity, and a late menopause.
Among the controls, the prevalence of oral contraceptive use varied with age (highest in the youngest women), geographic area (highest in Philadelphia, lowest in Boston), and year of interview (highest in later years); use was positively associated with number of years of education, alcohol consumption, and Jewish religion, and was inversely associated with body mass index (weight (kg)/height (m)
2 ), nulliparity, and high parity (data not shown).
Indicator terms were included in the logistic regression for variables which affected the relative risk estimates-age (in 5-year categories), geographic area of the hospital (Boston, New York, Philadelphia), interview year (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first full-term birth (<20, 20-24, 25-29, >30 years), nulliparity, and years of education (<12, 12, 13-15, >16). Terms were not included for variables which generally had little effect on the estimates: age at menarche, age at menopause, type of menopause, use of female hormone supplements, alcohol consumption, Jewish religion, breast cancer in a mother or sister, history of benign breast disease, body mass index, religion, and practice of breast self-examination. A continuous term was used in the logistic regression to test for trend in the relative risk estimates among oral contraceptive users. Interaction terms were used to test whether the association of oral contraceptive use with breast cancer risk varied by age or family history of breast cancer. Table 2 gives durations of oral contraceptive use according to age, with estimated relative risks for the duration categories relative to less than 1 year of use (never use combined with use for 1-11 months). Less than 1 year of use was used as the reference category in all analyses because the inclusion of short-term users would serve to reduce bias arising from cases who remembered short-term use better than controls, and it increased the size of the reference category for subanalyses. Estimates derived using never use as the reference category were similar to those derived using less than 1 year of use: For the age group 25-34 years, the estimates for use of Si year were 1.9 (95 percent confidence interval (CI) 1.3-2.6) and 1.7 (95 percent CI 1.3-2.3), respectively; for ages 35-44 years, the estimates were both 0.9; and for ages 45-59 years, they were both 1.2. The age-specific relative risk estimates for 1-11 months of use relative to never use ranged from 1.2 to 1.3.
RESULTS
As is shown in table 2, the overall duration-specific relative risk estimates for the categories 1-4, 5-9, and 10 years of use varied from 0.9 to 1.2; there was no trend (z = -0.93; p = 0.35). Among women aged 25-34 years, the overall relative risk for oral contraceptive use was 1.7 (95 percent CI 1.3-2.3); the duration-specific estimate increased to 2.5 (95 percent CI 1.4-4.8) for 10 or more years of use, but the trend was not statistically significant (z = 1.28; p = 0.17). Among women aged 35-44 years, the overall relative risk estimate was 0.9 (95 percent CI 0.7-1.0); the point estimate declined with increasing duration of use to 0.6 (95 percent CI 0.4-0.8) for 10 or more years of use, and the trend was statistically significant (z = -2.48; p = 0.013). For women aged 45-59 years, the overall estimate was 1.2 (95 percent CI 1.0-1.4); the point estimate was elevated for 5-9 years of use but not for 10 or more years of use, and there was no trend (z = -0.12; p = 0.90). These age-specific patterns were consistent across geographic areas. A test for interaction indicated that the association of 1 or more years of use with risk among women under age 35 differed significantly from that among women aged 35-44 and 45-59 years (p < 0.01), and that the latter two groups were similar to each other. Table 3 shows risk estimates according to age, duration of oral contraceptive use, and interview year. Among women aged 25-34 years, relative risks were elevated for long durations of use in each time period (1977-1980, 1981-1986, and 1987-1992) ; the association appeared weaker in the last period, but confidence intervals were wide. There was no consistent variation in the associations according to interview year in women aged 35-44 or 45-59 years. Table 4 gives relative risks according to age, duration of use, and whether women had used formulations containing <50 p~g of estrogen exclusively, formulations with ^50 /xg exclusively, or both types (including unknown formulations). The duration-specific relative risk estimates did not differ markedly across formulation categories in any of the age groups, but confidence intervals were wide. There were also no marked differences across formulations within categories of interview year (data not shown); however, these comparisons were limited by the sparsity of lower- • MVRR, multivariate relative risk estimate; Cl, confidence interval. t Adjusted for age (5-year categories), geographic area of hospital (Boston, New York, Philadelphia), interview year (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first full-term birth (<20, 20-24, 25-29, 230 years), nulliparity, and years of education (<12,12,13-15, 216).
$ Reference category.
dose use in the early years of the study and of higherdose use in the later years.
To evaluate whether the use of oral contraceptives at young ages is more strongly associated with an increased risk of breast cancer, we assessed use occurring before age 25, controlling for later use, and use at or after age 25, controlling for earlier use (table 5) . Among women aged 25-34 years, the duration-specific estimates were smaller for use before age 25 than for use after age 25, whereas the opposite was the case for women aged 45-59. For women aged 35-44 years, the estimates were close to or below 1.0. We also assessed use in three mutually exclusive categories: all use entirely before age 25, all use entirely after age 25, and use overlapping age 25 (data not shown). The relative risks were generally not higher for use before age 25. There was insufficient early use to carry out similar analyses examining use before age 20.
To assess whether age at first use of oral contraceptives influences risk, we evaluated both age at first use and the interval between menarche and first use (table 6) . There was no pattern of greater relative risks for use that began before age 18 or at ages 18-19 compared with use that began later, or vice versa. For the interval between menarche and first use of oral contraceptives, there was again no pattern of an increased risk for women who had shorter intervals between menarche and first use.
To evaluate whether use before the birth of a woman's first child is more strongly related to risk, we assessed use separately in nulliparous women and parous women (table 7) , and in the parous women according to whether use preceded or followed their first birth (table 8) . The estimates among nulliparous women were generally similar to the corresponding estimates among parous women. Among parous women, there was no consistent pattern in the relative risk estimates according to whether use preceded or followed the first birth.
To evaluate whether there was a latency effect, we estimated relative risks according to time interval since first use (table 9). The relative risk estimates did not vary consistently in any of the age groups as the length of the interval increased. Among women aged 25-34 years, the relative risk estimates of 1.6, 1.8, and 1.9 for the interval categories <10, 10-14, and 15-19 years, respectively, became 1.1, 1.3, and 1.3 after control for the duration of oral contraceptive use, and each of the latter estimates was compatible with 1.0. Table 9 also gives data on interval since last use of oral contraceptives. Among women aged 25-34 years, the relative risk estimate decreased from 1.9 to 1.3 as the length of the interval increased from <3 to 10-14 years. Among women aged 35-44 and 45-59 years, there was no consistent pattern across interval. Women aged 25-34 years are considered further in table 10, in which the duration of use is given within categories of interval since last use. The relative risk estimates were elevated for all duration categories within the interval <3 years: For durations of 1-4, 5-9, and ^10 years, the estimates were 1.7, 1.7, and 2.5, respectively, and all had a lower confidence limit of 1.0 or greater. Almost all long-duration use (^10 years) was in the interval category <3 years. For use of 5-9 years' duration, there were sufficient users in the interval categories <3, 3-4, and 5-9 years for relative risk estimation: The estimate was elevated in the first two intervals but not in the last. Table 11 shows relative risks according to age, duration of oral contraceptive use, and history of breast cancer in a mother or sister. Among women aged 25-34 years, the point estimates among women with a family history of breast cancer were greater than the corresponding estimates in women without such a history, but the difference was not statistically significant (p = 0.72). There were insufficient data for informative analysis according to the age at which the mother or sister developed breast cancer. Table 12 shows relative risks according to duration of oral contraceptive use and subsequent use of supplemental female hormones for at least 1 year among women aged 45-59 years; there was insufficient use in younger women for informative analysis. The relative risk estimate was 1.5 for 5 or more years of oral contraceptive use both among women who had used supplements for at least 1 year and among those who had not. Among women who had used supplements for 5 or more years, the relative risk estimate for oral contraceptive use of 5 or more years was 3.1 (95 percent Cl 0.8-13), based on 10 exposed cases and 7 exposed controls.
DISCUSSION
The results of studies published before early 1992 have recently been reviewed (1). Three studies have been published subsequently (11) (12) (13) . Results generally suggest that oral contraceptive users have an increased risk of breast cancer at young ages (1, 11, 13) . The results are more null, but not entirely so, for breast cancer at older ages, and there is even some evidence of a decreased risk among older women aged 45-54 years (14) . Findings are inconsistent with regard to t MVRR, multivariate relative risk estimate; Cl, confidence interval. i Adjusted for age (5-year categories), geographic area of hospital (Boston, New York, Philadelphia), interview year (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first full-term birth (<20, 20-24, 25-29, 230 years), nulllparity, and years of education (<12, 12, 13-15, 216).
§ Reference category.
categories of use that may confer increased risk and subgroups of women who may be especially vulnerable. In many studies, risk of breast cancer at younger ages has increased with the duration of use (1, 11, 13); in a notable exception, the Cancer and Steroid Hormone Study, there was no duration effect (14) . There is suggestive evidence that use at young ages may be more strongly associated with an increase (1, 11, 13), but this has not been established. In fact, two studies in which there were relatively large amounts of use during the teenage years found only a small increase in risk for such use relative to later use (15, 16) . In yet another study, use at young ages was related not to early breast cancer but rather to breast cancer at older ages (12) . The effect of use has varied according to its timing relative to the first birth in some studies, but not in others; recent studies have tended not to support a difference (1, 11, 13) . Data on the importance of the recency of use have also been inconsistent. Two recent studies (11, 13) suggested that recent use increases breast cancer risk at young ages (11, 13) ; there are also some data to support the possibility of such an effect on risk at older ages (17) . Yet other studies suggest a latency effect (18) . Some studies support a modifying effect of family history of breast cancer on an association with oral contraceptive use, but data are sparse (1, 11) . Data on a possible interaction between female hormone supplements and oral contraceptive use are also sparse. In the present study, oral contraceptive use was associated with an increased risk of breast cancer among women under age 35 years; the association was strongest for those who had used oral contraceptives longest, but the trend across duration of use was not statistically significant. Among women aged 35-44 years, the relative risk estimate declined significantly as the duration of use increased. Among women aged 45 years or more, some relative risk estimates were (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first full-term birth (<20, 20-24, 25-29, 230 years), nullipartty, and years of education (<12, 12, 13-15, 216).
§ Reference category. I Use at or after age 25 was controlled with the use of an indicator term. D Use before age 25 was controlled with the use of an indicator term.
elevated but there was no consistent pattern according to duration of use. The association in younger women appeared to be weaker in our more recent data, but the estimates were compatible with a uniform effect over time. When similar analyses were carried out among black women from the same surveillance system, the relative risk estimates were elevated in each of the time periods considered in the present study. There was no appreciable variation in the estimates between women who had used formulations with less than 50 /xg of estrogen exclusively and those who had used 50 pig or more exclusively, overall or over the course of the study. However, the numbers of exclusive users were small, and there was little lower-dose use early in the study or higher-dose use later in the study.
Our results do not support the hypothesis that use of oral contraceptives early in reproductive life has a more adverse effect on risk of breast cancer at younger ages: The relative risk estimates for use before age 25 were not greater than those for use after that age, and there were no consistent associations according to age at first use or interval between menarche and first use. We had insufficient data to assess use during the teenage years. There was also no evidence to suggest a latency effect-i.e., the risk of breast cancer increasing as the interval since first use increased.
There was also little support for a stronger association in nulliparous women or women who use oral contraceptives before the birth of their first child: Estimates were similar for nulliparous and parous women, and among the latter, use before the first birth was not more strongly associated with risk than use after.
If oral contraceptives act as promoters of tumor growth, an increased risk of breast cancer should be observed among recent users. In our data, the relative risk estimates were increased among women aged 25-34 who had used oral contraceptives within the previous 3 years, regardless of duration. However, the 95 percent confidence intervals were wide and duration of use was highly correlated with recency of use, making it infeasible to disentangle their effects. Among women aged 35-44 years, there was no evidence of an increase in risk regardless of the recency of use. There were too few recent users among women aged 45-59 years for analysis. 1 MVRR, multivariate relative risk estimate; Cl, confidence Interval. t Adjusted for age (5-year categories), geographic area of hospital (Boston, New York, Philadelphia), interview year, (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first full-term birth (<20, 20-24, 25-29, 230 years), nulliparity, and years of education (<12,12,13-15, 216). * Reference category.
There is some evidence that oral contraceptive use may be more harmful among women with a family history of breast cancer (11) . In the present study, among women aged 25-34 the point estimates were nonsignificantly higher among such women than among those without a family history, based on small numbers.
There has been concern that subsequent use of female hormone supplements may modify an adverse effect of oral contraceptives on breast cancer risk. In the present data, the relative risk estimates were comparable for women who had used oral contraceptives for at least 5 years regardless of whether they had subsequently used female hormone supplements for at least 1 year. There was a hint of a greater elevation among those who had used female hormone supplements for at least 5 years, but numbers were small and the results were compatible with chance.
In summary, our results suggest an increased risk of breast cancer at young ages among oral contraceptive (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first full-term birth (<20, 20-24, 25-29, 230 years) and years of education (<12 12,13-15,216).
t Reference category. t MVRR, multivariate relative risk estimate; Cl, confidence interval. t Adjusted for age (5-year categories), geographic area of hospital (Boston, New York, Philadelphia), interview year (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first fuli-term birth (<20, 20-24, 25-29, 230 years), and years of education (<12, 12, [13] [14] [15] 216) .
§ Reference category. I Use after the first birth was controlled with the use of an indicator term. H Use before the first birth was controlled with the use of an indicator term. * MVRR, multivariate relative risk estimate; Cl, confidence interval. t Adjusted for age (5-year categories), geographic area of hospital (Boston, New York, Philadelphia), interview year (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first fun-term birth (<20, 20-24, 25-29, 2:30 years), nulliparity, and years of education (<12, 12, 13-15, 2:16).
* Reference category.
users, possibly modified by the duration or recency of use. The results provide little support for an increased risk at older ages; in fact, among women aged 35-44 years, there was a suggestion of a decreased risk. Because the present study was hospital-based, selection bias could have affected either the case or the control series. The similarity of breast cancer risk factors in these data (19) with those in the large body of published evidence (20) provides some reassurance about the absence of material selection bias. The controls chosen had illnesses judged to be unrelated to oral contraceptive use, and the similarity of use across the diagnostic categories, including diagnoses for which hospital admission is usually obligatory, pro- (1977-1980, 1981-1982, 1983-1984, 1985-1986, 1987-1992) , age at first full-term birth (<20, 20-24, 25-29, 230 years), nulliparity, and years of education (<12,12,13-15, 216).
t Reference category.
vides some reassurance as to the validity of those judgments. The prevalence of ever use and long-duration use of oral contraceptives increased over time, as expected. However, we cannot assess whether these rates reflected those in the populations from which the women were drawn, because of noncomparability: Differences in factors such as ethnic group and religion have a major influence on the prevalence of oral contraceptive use. Because the controls were selected according to the same criteria over the course of the study, the variations in risk observed for the younger women over time are more Likely to be explained by chance than by bias associated with control selection (21). While we believe that selection bias is unlikely to explain the results, we are unable to rule out that possibility. The major known risk factors for breast cancer were controlled for in the analyses or were determined to have little influence on the magnitude of the relative risk estimates. Several potential risk factors-lactation, history of abortion, and interval since last birthwere not controlled (22) . The latter factors had no influence on the relative risk estimates in a study that did control for them (11) . Nonetheless, the magnitude of the association in our study and others is small enough that uncontrolled confounding must remain a concern.
Reporting bias may have occurred, because many women would have been aware of the hypothesized link between oral contraceptive use and breast cancer. The likely direction of such a bias would have been to inflate an association. Relative risk estimates were slightly increased in all age groups for women who had used oral contraceptives for less than 1 year, which is compatible with the cases' having been more likely than controls to remember short periods of use. However, long-term use was associated with an increase in risk only among women under age 35. Comparisons of data on oral contraceptive use obtained by both interview and record review in other studies (23, 24) suggest the absence of material reporting bias.
The possibility that early or increased detection of breast cancer among women who have used oral contraceptives contributes to the observed associations still remains to be ruled out. Some investigators have addressed this possibility, in part, by assessing tumor size at diagnosis or by controlling for use of medical care or breast self-examination (1) . Informative data on this question may be provided by epidemiologic studies that assess breast cancer mortality according to oral contraceptive use.
In addition, it remains to be determined whether an increase in risk at young ages, if real, persists as 
